Hydroxysteroid Dehydrogenase (17β-HSD3, 17β-HSD5, and 3α-HSD3) Inhibitors: Extragonadal Regulation of Intracellular Sex Steroid Hormone Levels
June 2007
in “
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery
”
Studysummary This review summarizes recent research and patents on 17β-HSD3, 17β-HSD5, and 3α-HSD3 inhibitors, suggesting their potential in treating androgen-dependent diseases, but reports no new clinical results.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on eurekaselect.com →